The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today, approved Livdelzi (seladelpar), developed by CymaBay Therapeutics, in adults for the treatment of a liver illness called ...

Last year featured slower merger and acquisition (M&A) activity than 2023 and a moderate uptick in alliances. Here, we highlight the trends and key deals. The transactions analysed include those ...

Investors with a lot of money to spend have taken a bearish stance on Affirm Holdings AFRM. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Affirm is one such popular 'buy now, pay later' option. Affirm gives customers the ability to pay off their loans in a typical time frame of three months to one year and is integrated into the ...

CymaBay Therapeutics has scrapped two mid-stage trials of seladelpar in non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), ending development of its lead drug.

Throughout the last three months, 18 analysts have evaluated Affirm Holdings (NASDAQ:AFRM), offering a diverse set of opinions from bullish to bearish. The following table provides a quick ...

SAN FRANCISCO--(BUSINESS WIRE)--Affirm Holdings, Inc. (Nasdaq: AFRM) (“Affirm” or the “Company”) today announced the pricing of $800 million aggregate principal amount of 0.75% Convertible ...

As part of the FDA accelerated approval, Gilead has initiated a confirmatory long-term outcomes study, called AFFIRM ... pipeline in March 2024, when CymaBay Therapeutics Inc. was acquired ...

SAN FRANCISCO--(BUSINESS WIRE)--Affirm Holdings, Inc. (Nasdaq: AFRM) (“Affirm” or the “Company”) today announced its intention to offer, subject to market conditions and other factors, $ ...

Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for rare liver disease primary biliary cholangitis (PBC), which has been filed for ...

NEWARK, Calif., Dec. 15, 2023 /PRNewswire/ — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, ...